Molecular pathways: At the crossroads of cancer epigenetics and immunotherapy

Michele Maio, Alessia Covre, Elisabetta Fratta, Anna Maria Di Giacomo, Pietro Taverna, Pier Giorgio Natali, Sandra Coral, Luca Sigalotti

Research output: Contribution to journalArticle

Abstract

Epigenetic regulation allows heritably modulating gene expression profiles without modifying the primary sequence of gDNA. Under physiologic conditions, epigenetic patterns determine tissue-specific gene expression landscapes, gene imprinting, inactivation of chromosome X, and preservation of genomic stability. The most characterized mediators of epigenetic inheritance are gDNA methylation and histone posttranslational modifications that cooperate to alter chromatin state and genome transcription. According to these notions, it is not surprising that cancer cells invariantly deploy epigenetic alterations to achieve gene expression patterns required for neoplastic transformation and tumor progression. In this context, the recently uncovered use of epigenetic alterations by cancer cells to become stealth from the host's immune recognition has significant immunobiologic relevance in tumor progression, and it appears to have potential clinical usefulness. Indeed, immune evasion is among the major obstacles to further improve the efficacy of cancer immunotherapies and to increase long-lasting disease control. Luckily, different "epigenetic drugs" able to revert these "epimutations" are available, some of which have already been approved for clinical use. Here, we summarize the immunomodulatory activities of epigenetic drugs that lead to improved immune recognition of cancer cells and focus on the potential of this class of agents in improving the anticancer activity of novel immunotherapies through combinatorial epigenetic immunotherapy approaches.

Original languageEnglish
Pages (from-to)4040-4047
Number of pages8
JournalClinical Cancer Research
Volume21
Issue number18
DOIs
Publication statusPublished - Sep 15 2015

Fingerprint

Epigenomics
Immunotherapy
Neoplasms
Histone Code
Immune Evasion
Gene Expression
Genomic Instability
X Chromosome
Gene Silencing
Post Translational Protein Processing
Transcriptome
Pharmaceutical Preparations
Methylation
Chromatin
Genome

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Molecular pathways : At the crossroads of cancer epigenetics and immunotherapy. / Maio, Michele; Covre, Alessia; Fratta, Elisabetta; Di Giacomo, Anna Maria; Taverna, Pietro; Natali, Pier Giorgio; Coral, Sandra; Sigalotti, Luca.

In: Clinical Cancer Research, Vol. 21, No. 18, 15.09.2015, p. 4040-4047.

Research output: Contribution to journalArticle

Maio, Michele ; Covre, Alessia ; Fratta, Elisabetta ; Di Giacomo, Anna Maria ; Taverna, Pietro ; Natali, Pier Giorgio ; Coral, Sandra ; Sigalotti, Luca. / Molecular pathways : At the crossroads of cancer epigenetics and immunotherapy. In: Clinical Cancer Research. 2015 ; Vol. 21, No. 18. pp. 4040-4047.
@article{fc940bf1e20b429b928b0d2ba0d9913a,
title = "Molecular pathways: At the crossroads of cancer epigenetics and immunotherapy",
abstract = "Epigenetic regulation allows heritably modulating gene expression profiles without modifying the primary sequence of gDNA. Under physiologic conditions, epigenetic patterns determine tissue-specific gene expression landscapes, gene imprinting, inactivation of chromosome X, and preservation of genomic stability. The most characterized mediators of epigenetic inheritance are gDNA methylation and histone posttranslational modifications that cooperate to alter chromatin state and genome transcription. According to these notions, it is not surprising that cancer cells invariantly deploy epigenetic alterations to achieve gene expression patterns required for neoplastic transformation and tumor progression. In this context, the recently uncovered use of epigenetic alterations by cancer cells to become stealth from the host's immune recognition has significant immunobiologic relevance in tumor progression, and it appears to have potential clinical usefulness. Indeed, immune evasion is among the major obstacles to further improve the efficacy of cancer immunotherapies and to increase long-lasting disease control. Luckily, different {"}epigenetic drugs{"} able to revert these {"}epimutations{"} are available, some of which have already been approved for clinical use. Here, we summarize the immunomodulatory activities of epigenetic drugs that lead to improved immune recognition of cancer cells and focus on the potential of this class of agents in improving the anticancer activity of novel immunotherapies through combinatorial epigenetic immunotherapy approaches.",
author = "Michele Maio and Alessia Covre and Elisabetta Fratta and {Di Giacomo}, {Anna Maria} and Pietro Taverna and Natali, {Pier Giorgio} and Sandra Coral and Luca Sigalotti",
year = "2015",
month = "9",
day = "15",
doi = "10.1158/1078-0432.CCR-14-2914",
language = "English",
volume = "21",
pages = "4040--4047",
journal = "Clinical Cancer Research",
issn = "1078-0432",
publisher = "American Association for Cancer Research Inc.",
number = "18",

}

TY - JOUR

T1 - Molecular pathways

T2 - At the crossroads of cancer epigenetics and immunotherapy

AU - Maio, Michele

AU - Covre, Alessia

AU - Fratta, Elisabetta

AU - Di Giacomo, Anna Maria

AU - Taverna, Pietro

AU - Natali, Pier Giorgio

AU - Coral, Sandra

AU - Sigalotti, Luca

PY - 2015/9/15

Y1 - 2015/9/15

N2 - Epigenetic regulation allows heritably modulating gene expression profiles without modifying the primary sequence of gDNA. Under physiologic conditions, epigenetic patterns determine tissue-specific gene expression landscapes, gene imprinting, inactivation of chromosome X, and preservation of genomic stability. The most characterized mediators of epigenetic inheritance are gDNA methylation and histone posttranslational modifications that cooperate to alter chromatin state and genome transcription. According to these notions, it is not surprising that cancer cells invariantly deploy epigenetic alterations to achieve gene expression patterns required for neoplastic transformation and tumor progression. In this context, the recently uncovered use of epigenetic alterations by cancer cells to become stealth from the host's immune recognition has significant immunobiologic relevance in tumor progression, and it appears to have potential clinical usefulness. Indeed, immune evasion is among the major obstacles to further improve the efficacy of cancer immunotherapies and to increase long-lasting disease control. Luckily, different "epigenetic drugs" able to revert these "epimutations" are available, some of which have already been approved for clinical use. Here, we summarize the immunomodulatory activities of epigenetic drugs that lead to improved immune recognition of cancer cells and focus on the potential of this class of agents in improving the anticancer activity of novel immunotherapies through combinatorial epigenetic immunotherapy approaches.

AB - Epigenetic regulation allows heritably modulating gene expression profiles without modifying the primary sequence of gDNA. Under physiologic conditions, epigenetic patterns determine tissue-specific gene expression landscapes, gene imprinting, inactivation of chromosome X, and preservation of genomic stability. The most characterized mediators of epigenetic inheritance are gDNA methylation and histone posttranslational modifications that cooperate to alter chromatin state and genome transcription. According to these notions, it is not surprising that cancer cells invariantly deploy epigenetic alterations to achieve gene expression patterns required for neoplastic transformation and tumor progression. In this context, the recently uncovered use of epigenetic alterations by cancer cells to become stealth from the host's immune recognition has significant immunobiologic relevance in tumor progression, and it appears to have potential clinical usefulness. Indeed, immune evasion is among the major obstacles to further improve the efficacy of cancer immunotherapies and to increase long-lasting disease control. Luckily, different "epigenetic drugs" able to revert these "epimutations" are available, some of which have already been approved for clinical use. Here, we summarize the immunomodulatory activities of epigenetic drugs that lead to improved immune recognition of cancer cells and focus on the potential of this class of agents in improving the anticancer activity of novel immunotherapies through combinatorial epigenetic immunotherapy approaches.

UR - http://www.scopus.com/inward/record.url?scp=84942853841&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84942853841&partnerID=8YFLogxK

U2 - 10.1158/1078-0432.CCR-14-2914

DO - 10.1158/1078-0432.CCR-14-2914

M3 - Article

C2 - 26374074

AN - SCOPUS:84942853841

VL - 21

SP - 4040

EP - 4047

JO - Clinical Cancer Research

JF - Clinical Cancer Research

SN - 1078-0432

IS - 18

ER -